PT-141 peptide for women is FDA-approved as Vyleesi for low sexual desire. Learn dosing, side effects, onset, and what compounded versions do not do.
PT-141 is a synthetic peptide that the FDA approved in 2019 as bremelanotide, sold under the brand name Vyleesi, for premenopausal women with hypoactive sexual desire disorder (HSDD). It is given as a subcutaneous injection into the thigh or abdomen about 45 minutes before anticipated sexual activity. PT-141 does not work like hormones or like erectile dysfunction drugs, because it acts on melanocortin receptors in the brain that help regulate sexual desire.
What Is the PT-141 Peptide?
PT-141, also called bremelanotide, is a modified form of alpha-melanocyte-stimulating hormone, a compound the body makes naturally. Researchers first studied it for tanning and appetite effects before noticing changes in sexual desire during early trials.
The basics:
- Drug class: melanocortin receptor agonist, with activity mainly at MC4R and MC1R.
- Brand name: Vyleesi (bremelanotide injection), a 1.75 mg auto-injector pen.
- Approved population: premenopausal women with acquired, generalized HSDD.
- Not approved for: men, postmenopausal women, or general libido enhancement in people without a diagnosis.
Is PT-141 Approved for Women in the United States?
Yes, but only in one narrow, prescription-only form. The PT-141 peptide for women is legally available as Vyleesi, and it is not sold over the counter. The FDA approval covers premenopausal women whose low desire causes personal distress, not women who simply want a stronger libido.
Interest in pt 141 for women has grown quickly online, and much of that interest centers on compounded products rather than the approved drug. Compounded PT-141 is not FDA-approved, so its strength, purity, and sterility have not been reviewed by the agency.
PT-141 is not approved for men, and it is not a treatment for erectile dysfunction or premature ejaculation.
How PT-141 Works Differently Than Other Options
PT-141 works through the central nervous system rather than through blood flow. It binds melanocortin receptors in the hypothalamus and related brain regions involved in desire, which is why the label describes it as a treatment for low sexual desire instead of for arousal or lubrication problems alone.
That mechanism explains a few practical points:
- It is not a hormone and does not raise estrogen or testosterone.
- It does not act like PDE5 inhibitors such as sildenafil, which target blood vessels.
- It is not a lubricant or a local therapy for vaginal dryness.
- It does not replace counseling, relationship support, or treatment of underlying conditions.
Dosing and Onset: How Fast Does It Work?
The approved dose is 1.75 mg injected under the skin at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours, and do not use more than eight doses in a month.
| Question | Approved answer |
|---|---|
| Dose | 1.75 mg subcutaneous injection |
| Timing | About 45 minutes before activity |
| Maximum frequency | Once per 24 hours; up to 8 doses per month |
| Typical onset | Often within 45 to 60 minutes; effects can last a few hours |
| Missed dose | Skip it and do not double up |
Individual response varies widely. Some women notice a difference within the first few doses, while others need several weeks of occasional use before they can judge whether it helps. Many people ask how fast does pt-141 work for women and expect an instant effect, but onset and benefit differ from person to person.
A pt-141 peptide dosage chart found online is not a substitute for the prescribing label. Higher doses were studied and did not clearly improve results, while nausea became more common.
PT-141 Side Effects and Safety
The most common pt-141 for women side effects are nausea, flushing, headache, and injection site reactions. Nausea is the side effect most likely to make people stop treatment, and it tends to be worse when alcohol is involved.
Other safety points to know:
- PT-141 can raise blood pressure and temporarily lower heart rate after a dose.
- It is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease.
- Darkening of the skin, gums, or breast tissue has been reported with melanocortin drugs, sometimes after stopping.
- Focal seizures occurred in a small number of trial participants.
- It should not be combined with other injectable melanocortin products.
PT-141 is a prescription medicine, and it should be used under the care of a clinician who can review blood pressure, current medications, and cardiovascular history.
Compounded PT-141, Nasal Sprays, and Online Sellers
Much of what is marketed as research-grade peptide is not the approved drug. A pt-141 peptide nasal spray is a compounded or gray-market product, and the original intranasal bremelanotide development program was discontinued years ago, partly over blood pressure concerns.
| Product type | FDA status | Typical dose | What to know |
|---|---|---|---|
| Vyleesi (bremelanotide) auto-injector | Approved for premenopausal women with HSDD | 1.75 mg subcutaneously | Prescription only, with labeled dosing and safety data |
| Compounded injectable PT-141 | Not approved | Varies by seller | No guaranteed strength, purity, or sterility |
| Compounded nasal spray | Not approved | Varies by seller | Absorption is inconsistent, and blood pressure effects are still possible |
Search online for vials and you will mostly find products labeled "for research use only." Those items are not intended for human use, and buying them means accepting unknown purity and dosing risks.
Some men look into PT-141 for erectile difficulties or for premature ejaculation. Neither use is FDA-approved, and the evidence supporting both is limited.
Who Should Talk to a Doctor First
Speak with a clinician before trying PT-141 if you take blood pressure medication, have any cardiovascular condition, are pregnant or breastfeeding, or have a history of seizures or dark skin patches. PT-141 has not been studied in pregnancy and is not recommended while breastfeeding.
PT-141 may help some premenopausal women with distressing low desire, and it is not a solution for every cause of low libido. Hormonal shifts, medications, depression, relationship stress, and other medical conditions can all reduce desire, and each of those causes deserves its own evaluation.
Frequently Asked Questions
Is PT-141 FDA-approved for women?
Yes. Bremelanotide, sold as Vyleesi, is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder that causes personal distress. It is a prescription injection and is not approved for men, postmenopausal women, or general libido enhancement.
How fast does PT-141 work for women?
The label directs users to inject 1.75 mg about 45 minutes before anticipated sexual activity, and many women notice effects within 45 to 60 minutes. Individual response varies, and some women need several uses over a few weeks before they can tell whether it helps.
Can I buy PT-141 peptide online without a prescription?
No. Bremelanotide is a prescription drug in the United States, and vials sold online are usually labeled for research use only and are not intended for human consumption. Compounded PT-141 injections and nasal sprays are not FDA-approved, so their strength, purity, and sterility are not guaranteed.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.